Evidence map›Paper›PMID 37733303›Full record

Trial reportJournal of integrative and complementary medicine2024

A Prospective, Multicentered, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Keluoxin Capsules in the Treatment of Microalbuminuria in Patients with Type 2 Early Diabetic Kidney Disease.

Jinxi Zhao, Shidong Wang, Xiaoran Li, Guangde Zhang, Yuan Xu, Xianling Zheng, Jian Guo, Zhenxian Zhang

Open access · hybridAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of integrative and complementary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Jinxi ZhaoDepartment of Nephropathy and Endocrinology, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China.ORCID 0000-0002-0593-2152
Shidong WangDepartment of Nephropathy and Endocrinology, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China.
Xiaoran LiDepartment of Nephropathy and Endocrinology, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China.
Guangde ZhangDepartment of Endocrinology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Yuan XuDepartment of TCM Diabetes, China-Japan Friendship Hospital, Beijing, China.
Xianling ZhengDepartment of Endocrinology, Handan Central Hospital, Handan, China.
Jian GuoDepartment of Endocrine and Metabolic Diseases, Tianjin Hospital of ITCWM Nankai Hospital, Tianjin, China.
Zhenxian ZhangDiabetes Clinic, Luohe Hospital of Traditional Chinese Medicine, Luohe, China.
Beijing University of Chinese Medicine · CNChina-Japan Friendship Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHandan College · CNLuohe Medical College · CNTianjin Nankai Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesAlbuminuriaFemaleHumansIrbesartanMaleProspective StudiesQuality of LifeTreatment OutcomeIrbesartandiabetic kidney diseaseKeluoxin capsulesmicroalbuminuriarandomized controlled trial

Identifiers

PMID37733303
PMCPMC10884549
OpenAlexW4386910984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.